Bad risk: The jcv test is not very definitive. Tysabri (natalizumab) lowers immune response and can cause activation of latent virus agents and prions. The risk is significant regardless of the jcv status.
Answered 5/18/2013
5.6k views
A doctor has provided 1 answer
A doctor has provided 1 answer
A doctor has provided 1 answer
A doctor has provided 1 answer
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question